# US 2024/0252673 A1 · Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0252673 A1
- Document ID: US20240252673A1
- Status: Published application
- Kind: A1
- Application number: 18/451,780
- Filed: 2023-08-17
- Published: 2024-08-01
- Earliest claimed: 2017-11-02
- Assignees: Genmab A/S
- Applicants: Genmab A/S
- Inventors: Reshma A. RANGWALA; Steen LISBY
- Web page: https://patentgrep.com/patent/US20240252673A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/6811: {the drug being a protein or peptide, e.g. transferrin or bleomycin}
- A61K 47/6843: {the antibody targeting a material from animals or humans}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6869: {the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07K 16/32: against translation products of oncogenes
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/565: Complementarity determining region [CDR]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides methods and compositions for treating cancer, such as advanced cervical cancer, in a subject, such as by the administration of antibody-drug conjugates that bind to tissue factor (TF). The invention also provides articles of manufacture and compositions comprising said antibody drug-conjugates that bind to TF for use in treating cancer (e.g., advanced cervical cancer).

## Claims

### Claim 1

A method of treating cervical cancer in a subject, the method comprising administering to the subject an antibody-drug conjugate that binds to tissue factor (TF), wherein the antibody-drug conjugate comprises an anti-TF antibody or an antigen-binding fragment thereof conjugated to a monomethyl auristatin or a functional analog thereof or a functional derivative thereof, and wherein the antibody-drug conjugate is administered at a dose ranging from about 1.5 mg/kg to about 2.1 mg/kg.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of claim 1, wherein the antibody-drug conjugate is administered once about every 1 week, 2 weeks, 3 weeks or 4 weeks.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject has been previously treated with one or more therapeutic agents and did not respond to the treatment, wherein the one or more therapeutic agents is not the antibody-drug conjugate.

### Claim at position 6

6-11. (canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein the subject is ineligible for treatment with bevacizumab.

### Claim 13 (depends on 1)

The method of claim 1, wherein the subject is not a candidate for curative therapy.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The method of claim 1, wherein the subject did not respond to treatment with no more than two prior systemic treatment regimens.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The method of claim 1, wherein the cervical cancer is an adenocarcinoma, an adenosquamous carcinoma or a squamous cell carcinoma.

### Claim 18 (depends on 1)

The method of claim 1, wherein the cervical cancer is an advanced stage cervical cancer, metastatic cervical cancer or a recurrent cervical cancer.

### Claim 19

(canceled)

### Claim 20 (depends on 1)

The method of claim 1, wherein the monomethyl auristatin is monomethyl auristatin E (MMAE).

### Claim 21 (depends on 1)

The method of claim 1, wherein the anti-TF antibody or antigen-binding fragment thereof of the antibody-drug conjugate is a monoclonal antibody or a monoclonal antigen-binding fragment thereof.

### Claim 22 (depends on 1)

The method of claim 1, wherein the anti-TF antibody or antigen-binding fragment thereof of the antibody-drug conjugate comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises:
(i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:1;
(ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:2; and
(iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:3; and
wherein the light chain variable region comprises:
(i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:4;
(ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:5; and
(iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:6, wherein the CDRs of the anti-TF antibody or antigen-binding fragment thereof of the antibody-drug conjugate are defined by the IMGT numbering scheme.

### Claim 23

(canceled)

### Claim 24 (depends on 1)

The method of claim 1, wherein the anti-TF antibody or antigen-binding fragment thereof of the antibody-drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:7 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:8.

### Claim 25 (depends on 1)

The method of claim 1, wherein the anti-TF antibody of the antibody-drug conjugate is tisotumab.

### Claim 26 (depends on 1)

The method of claim 1, wherein the antibody-drug conjugate further comprises a linker between the anti-TF antibody or antigen-binding fragment thereof and the monomethyl auristatin.

### Claim 27 (depends on 26)

The method of claim 26, wherein the linker is a cleavable peptide linker.

### Claim 28 (depends on 27)

The method of claim 27, wherein the cleavable peptide linker has a formula: -MC-vc-PAB-, wherein:
a) MC is:
b) vc is the dipeptide valine-citrulline, and
c) PAB is:

### Claim 29 (depends on 28)

The method of claim 28, wherein the linker is attached to sulphydryl residues of the anti-TF antibody obtained by partial reduction or full reduction of the anti-TF antibody or antigen-binding fragment thereof.

### Claim 30 (depends on 29)

The method of claim 29, wherein the linker is attached to MMAE, wherein the antibody-drug conjugate has the following-structure:
wherein p denotes a number from 1 to 8, S represents a sulphydryl residue of the anti-TF antibody, and Ab designates the anti-TF antibody or antigen-binding fragment thereof.

### Claim 31

(canceled)

### Claim 32 (depends on 1)

The method of claim 1, wherein the antibody-drug conjugate is tisotumab vedotin.

### Claim at position 28

33-50. (canceled)

### Claim 51 (depends on 1)

A kit comprising:
(a) a medicament comprising an antibody-drug conjugate, wherein the antibody drug conjugate comprises an anti-TF antibody or an antigen-binding fragment thereof conjugated to a monomethyl auristatin or a functional analog thereof or a functional derivative thereof; and
(b) a package insert comprising instructions for administration of the medicament comprising the antibody-drug conjugate in a method of treating cervical cancer in a subject according to the method of claim 1.
